Matthew L. Ulrickson
About
Matthew L. Ulrickson is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology.
According to data from OpenAlex, Matthew L. Ulrickson has authored 35 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in Matthew L. Ulrickson's work include CAR-T cell therapy research (21 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Matthew L. Ulrickson is often cited by papers focused on CAR-T cell therapy research (21 papers), Lymphoma Diagnosis and Treatment (12 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Matthew L. Ulrickson collaborates with scholars based in United States, Canada and France. Matthew L. Ulrickson's co-authors include Olalekan O. Oluwole, Natasha Kekre, Sattva S. Neelapu, Yi Lin, Chaitra S. Ujjani, Julio C. Chávez, Alex F. Herrera, Peter A. Riedell, Michael Dickinson and Sven de Vos and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Matthew L. Ulrickson
27 papers receiving 396 citations
Hit Papers
Peers
Matthew L. Ulrickson
Alessandro Crotta United States
Alessandro Previtali United States
Bryan Do United States
Christine Dehner United States
Barbara S. Pender United States
Houston Holmes United States
Paul Maciocia United Kingdom
Robin Sanderson United Kingdom
Maria A. V. Marzolini United Kingdom
Noemi Mergen Germany
Citations per year, relative to Matthew L. Ulrickson Matthew L. Ulrickson (= 1×)
peers
Alessandro Crotta
Countries citing papers authored by Matthew L. Ulrickson
Since
Specialization
Citations
This map shows the geographic impact of Matthew L. Ulrickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew L. Ulrickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew L. Ulrickson more than expected).
Fields of papers citing papers by Matthew L. Ulrickson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew L. Ulrickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew L. Ulrickson. The network helps show where Matthew L. Ulrickson may publish in the future.
Co-authorship network of co-authors of Matthew L. Ulrickson
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew L. Ulrickson. A scholar is included among the top collaborators of Matthew L. Ulrickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew L. Ulrickson. Matthew L. Ulrickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chávez, Julio C., Michael Dickinson, Javier Muñoz, et al.. (2025). Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 145(20). 2303–2311.
2.
Garciaz, Sylvain, Pierre Péterlin, Daniel Morillo, et al.. (2025). γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction. Blood. 146(Supplement 1). 652–652.
3.
Pemmaraju, Naveen, Giovanni Marconi, Pau Montesinos, et al.. (2025). Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study.. Journal of Clinical Oncology. 43(16_suppl). 6502–6502.
4.
Hecht, J. Randolph, Patrick Grierson, Theodore H. Welling, et al.. (2025). Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors.. Journal of Clinical Oncology. 43(4_suppl). 766–766.
5.
Simeone, Diane M., Patrick Grierson, Kedar Kirtane, et al.. (2024). Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). 1604–1604.
6.
Ulrickson, Matthew L., Muhammad Husnain, Madiha Iqbal, et al.. (2023). Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis. Transplantation and Cellular Therapy. 29(2). S327–S328.
7.
Westin, Jason R., Olalekan O. Oluwole, Marie José Kersten, et al.. (2023). PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. Hematological Oncology. 41(S2). 52–54.
8.
Neelapu, Sattva S., Michael Dickinson, Javier Muñoz, et al.. (2022). Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine. 28(4). 735–742.
9.
Westin, Jason R., Frederick L. Locke, Michael Dickinson, et al.. (2022). Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).. Journal of Clinical Oncology. 40(16_suppl). 7548–7548.
10.
Hernandez‐Ilizaliturri, Francisco J., John Kuruvilla, Beth Christian, et al.. (2022). P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL). HemaSphere. 6. 1039–1040.
11.
Kadia, Tapan M., Christopher B. Benton, Harry P. Erba, et al.. (2022). Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). Blood. 140(Supplement 1). 11659–11660.
12.
Ulrickson, Matthew L., Muhammad Husnain, Madiha Iqbal, et al.. (2022). Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis. Blood. 140(Supplement 1). 12111–12113.
13.
Ulrickson, Matthew L., et al.. (2021). Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma. Cureus. 13(5). e15174–e15174.
14.
Neelapu, Sattva S., Michael Dickinson, Javier Muñoz, et al.. (2021). Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). Blood. 138(Supplement 1). 739–739.
15.
Hernandez‐Ilizaliturri, Francisco J., Ian W. Flinn, John Kuruvilla, et al.. (2020). A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. Blood. 136(Supplement 1). 41–42.
16.
Neelapu, Sattva S., Michael Dickinson, Matthew L. Ulrickson, et al.. (2020). Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). Blood. 136(Supplement 1). 49–49.
17.
Ulrickson, Matthew L., Fred Okuku, Oliver W. Press, et al.. (2013). Cutaneous T-Cell Lymphoma in Sub-Saharan Africa. Journal of the National Comprehensive Cancer Network. 11(3). 275–280.
18.
Ulrickson, Matthew L., Oliver W. Press, & Corey Casper. (2012). Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Advances in Hematology. 2012. 1–7.
19.
Ulrickson, Matthew L., Julie Aldridge, Haesook T. Kim, et al.. (2009). Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. Biology of Blood and Marrow Transplantation. 15(11). 1447–1454.
20.
Baehring, Joachim M., Ephraim P. Hochberg, Noopur Raje, Matthew L. Ulrickson, & Fred H. Hochberg. (2008). Neurological manifestations of Waldenström macroglobulinemia. Nature Clinical Practice Neurology. 4(10). 547–556.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Alessandro Previtali Breakdown of academic impact, for papers by Bryan Do Breakdown of academic impact, for papers by Christine Dehner Breakdown of academic impact, for papers by Barbara S. Pender Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by Paul Maciocia Breakdown of academic impact, for papers by Robin Sanderson Breakdown of academic impact, for papers by Maria A. V. Marzolini Breakdown of academic impact, for papers by Noemi Mergen